Wells Fargo & Company Atreca, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.13 - $0.38 $1 - $5	14 Added 0.63%	2,251 $0
Q3 2023 Nov 13, 2023	BUY	$0.26 - $1.12 $5 - $24	22 Added 0.99%	2,237 $0
Q2 2023 Aug 15, 2023	SELL	$0.88 - $1.22 $2,896 - $4,015	-3,291 Reduced 59.77%	2,215 $2,000
Q1 2023 May 12, 2023	BUY	$0.91 - $1.82 $460 - $920	506 Added 10.12%	5,506 $6,000
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $659 - $1,419	-845 Reduced 14.46%	5,000 $4,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $790 - $1,361	-497 Reduced 7.84%	5,845 $8,000
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $8,884 - $18,508	-5,695 Reduced 47.31%	6,342 $11,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $21,569 - $69,664	-13,397 Reduced 52.67%	12,037 $38,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $19,214 - $42,111	6,695 Added 35.73%	25,434 $77,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $46,738 - $86,337	-9,519 Reduced 33.69%	18,739 $117,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $31,686 - $55,917	-4,052 Reduced 12.54%	28,258 $241,000
Q1 2021 May 13, 2021	SELL	$13.0 - $19.34 $129,961 - $193,341	-9,997 Reduced 23.63%	32,310 $495,000
Q4 2020 Feb 09, 2021	BUY	$13.03 - $17.09 $316,707 - $415,389	24,306 Added 135.03%	42,307 $683,000
Q3 2020 Nov 05, 2020	SELL	$12.67 - $23.19 $37,959 - $69,477	-2,996 Reduced 14.27%	18,001 $251,000
Q2 2020 Aug 13, 2020	SELL	$12.52 - $23.45 $31,162 - $58,367	-2,489 Reduced 10.6%	20,997 $447,000
Q1 2020 May 14, 2020	BUY	$11.4 - $27.28 $267,740 - $640,698	23,486 New	23,486 $389,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.